Glenmark Pharmaceuticals Ltd

Mid Cap

Healthcare Sector

reflects a positive outlook for the share price

reflects a neutral outlook for the share price

reflects a negative outlook for the share price

The analysts information is for reference only and does not\n  represents an investment recommendation.

Analyst recommendation reflect the views of analysts who follow and write research reports.

Company Information is an introduction to the company’s business that details what it sell, how it was founded, what their mission is, how they manufacture or source their products, and why they serve customers.

Glenmark Pharmaceuticals' Chhatrapati Sambhajinagar facility successfully cleared a US FDA Pre-Approval Inspection with zero observations, indicating strong compliance and readiness for US market approvals.

Glenmark's Facility Passes US FDA Inspection Successfully - 01 Dec, 2025

Glenmark Pharmaceuticals received a positive EIR from the USFDA for its Monroe facility, allowing commercial manufacturing to resume. Shares rose 1.93%, with analysts recommending buying at current levels.

Glenmark Receives Positive FDA Report, Shares Rise - 27 Nov, 2025

Glenmark Pharmaceuticals has launched Nebzmart GFB Smartules and Airz FB Smartules, the world's first nebulized fixed-dose triple therapy for COPD, enhancing patient care and simplifying treatment.

Glenmark Launches Innovative COPD Treatment - 25 Nov, 2025

Glenmark Pharmaceuticals reported a strong revenue growth but faced disruptions in India. HSBC cut its target price to Rs 2,110, highlighting operational challenges.

Glenmark Faces Target Price Cut Amid Disruptions - 19 Nov, 2025

Glenmark Pharmaceuticals received European Commission approval for Winlevi, its first new chemical entity in Europe, allowing sales in 15 countries for acne treatment.

Glenmark Secures EU Approval for Acne Drug Winlevi - 18 Nov, 2025

Glenmark Pharmaceuticals announced a 72.2% increase in Q2 profit to ₹610.43 crore, attributed to a licensing deal with AbbVie. The stock gained 2.55%, continuing its upward trend.

Glenmark Pharmaceuticals Reports Strong Q2 Results - 14 Nov, 2025

Glenmark Pharmaceuticals' subsidiary has received approval from China's NMPA for Ryaltris nasal spray, a significant milestone in expanding its respiratory portfolio in a key market.

Glenmark Secures China Approval for Ryaltris Nasal Spray - 10 Nov, 2025

Glenmark Pharmaceuticals is set to launch its 8.4% Sodium Bicarbonate Injection in the US this November, despite a recent decline in share prices and a significant profit drop.

Glenmark Launches Sodium Bicarbonate Injection Amid Stock Decline - 04 Nov, 2025

Glenmark Pharmaceuticals Ltd rose 0.02%, marking its fifth consecutive session of gains. The stock is up 11.31% over the past year, outperforming both NIFTY and the Nifty Pharma index. However, it has slipped 4.04% in the last month.

Glenmark Pharmaceuticals Continues Upward Trend - 03 Nov, 2025

Price to Earnings Ratio or Price to Earnings Multiple is the ratio of the share price of a stock to its earnings per share (EPS). It provides an indication of whether a stock at its current market price is expensive or cheap.

The price/earnings-to-growth ratio, or the PEG ratio, is a metric that helps investors value a stock by taking into account a company's market price, its earnings, and its future growth prospects.

Enterprise value (EV) is the total value of a company, defined in terms of its financing. It includes both the current share price (market capitalization) and the cost to pay off debt (net debt, or debt minus cash).

Alpha measures the amount that the investment has returned in comparison to the market index or other broad benchmark that it is compared against.

Beta measures a stock's volatility, the degree to which its price fluctuates in relation to the overall stock market. In other words, it gives a sense of the stock's risk compared to that of the greater market.

Dividend yield measures the quantum of earnings by way of total dividends that investors make by investing in that company.

The debt-to-total-assets ratio shows how much of a business is owned by creditors (people it has borrowed money from) compared with how much of the company's assets are owned by shareholders.

Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations.

This widget shows the information about the stock's peers in consideration along with the different data for those peers so that the user can compare the stock with the other similar stock and invest accordingly.

Promoter holding is the amount of share of the company that is owned by the promoters. The promoters are the company's founders, who hold a majority stake in the company's capital.

A foreign institutional investor (FII) is an investor or investment fund investing in a country outside of the one in which it is registered or headquartered.

A mutual fund is a pool of money managed by a professional Fund Manager. It is a trust that collects money from a number of investors who share a common investment objective and invests the same in equities, bonds, money market instruments, and other securities.

Retail investors execute their trades through traditional or online brokerage firms or other types of investment accounts. Retail investors purchase securities for their own personal accounts and often trade in dramatically smaller amounts as compared to institutional investors.

This widget shows the bifurcation of stocks based on the percentage of stake with the different types of shareholders.

This widget will help value the stock based on the Price to Earning ratio of the stock and compare the valuation with the industry value and other similar stocks. It even shows the timeline of the valuation of the stock and its highest and lowest valuation over time.
A Time Series data is provided which compares the historical stock PE with Industry PE over the period of 5 years.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

In the last 1 month, GLENMARK stock has moved up by 8.7%

This section gives you an insight into the price movement of the stock for the last few quarters.

Price Rise

In the last 3 years, GLENMARK has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

This section gives you an insight into why this company has been the best in its industry for the last 3 years.

Best in 3 Years

Foreign Institutions have increased holdings from 20.62% to 20.73% in Sep 2025 quarter

This section gives you an insight into how the FII Holding has changed for the stock over last few quarters.

FII Holding Up

Mutual Funds have increased holdings from 15.55% to 16.31% in Sep 2025 quarter

This section gives you an insight into how the Mutual Funds Holding has changed for the stock over last few quarters.

MF Holding Up

Netprofit is up for the last 3 quarters, 4.65 Cr → 610.35 Cr (in ₹), with an average increase of 91.2% per quarter

This section gives you an insight into how the profit for the company has been for the last few quarters.

Profit Spike

Revenue is up for the last 3 quarters, 3.26K Cr → 6.24K Cr (in ₹), with an average increase of 24.0% per quarter

This section gives you an insight into how the revenue of the company has moved for the last few quarters.

Revenue Rich

In the last 1 year, GLENMARK has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

This section gives you an insight into why this company has been the best in its industry for the last 1 year.

Best in 1 Year

Promoters holdings remained unchanged at 46.65% of holdings in Sep 2025 quarter

This section gives you an insight into how the Promoter Holding has changed for the stock over the last few quarters.

Promoter Holding Unchanged

Retail Investor have decreased holdings from 15.06% to 13.97% in Sep 2025 quarter

This section gives you an insight into how the Retail Investors Holding has changed for the stock over last few quarters.

Retail Holding Down

Nifty Alpha 50

NIFTY PHARMA

Nifty LargeMidcap 250

S&P BSE 400 MidSmallCap

Nifty Midcap 150

BSE Healthcare

Nifty Healthcare

Nifty Midcap 100

BSE Mid-Cap

BSE 500

Nifty 200

S&P BSE 250 LargeMidCap

Nifty MidSmallcap 400

S&P BSE 150 MidCap

S&P BSE Momentum

Nifty 500

HDFC Mid Cap Fund -Direct Plan - Growth Option

Kotak Arbitrage Fund Direct Growth

Invesco India Mid Cap Fund Direct Plan Growth Option

Invesco India Contra Fund Direct Plan Growth

HDFC Manufacturing Fund Direct Growth

Glenmark Pharmaceuticals Ltd’s net profit jumped 72.31% since last year same period to ₹610.35Cr in the Q2 2025-2026. On a quarterly growth basis, Glenmark Pharmaceuticals Ltd has generated 1202.22% jump in its net profits since last 3-months.

Glenmark Pharmaceuticals Ltd Earnings Results

In the quarter ending June 2025, Glenmark Pharmaceuticals Ltd has declared dividend of ₹2.50 per share on 26 Sep 2025 - translating a dividend yield of 0.25%.

Name	Value	Action
MACD level (12,26)	-1.86	Bearish
CCI (20)	-55.89	Neutral
RSI (14)	28.66	Bullish
Momentum (10)	-15.9	Bearish
ADI (14)	34.04	Bearish
Ultimate Oscillator (7,14,28)	20.01	Bearish

Name	Value	Action
SMA (20)	1969.9	Bearish
EMA (20)	1967.24	Bearish
VWMA (20)	1967.57	Bearish
SMA (50)	1967.26	Bearish
EMA (50)	1968.74	Bearish
SMA (200)	1974.37	Bearish
EMA (200)	1972.69	Bearish
KAMA (200)	1966.48	Bearish
DEMA (200)	1970.57	Bearish

Glenmark Pharmaceuticals Ltd (GLENMARK)

Summary

Overall

Oscillators

Moving Averages